The most prevalent genetic rearrangement in prostate cancer involves the fusion of the androgen-regulated gene TMPRSS2 with the ETS transcription factor ERG, which is estimated to occur in ~50% of prostate cancer cases (Tomlins et al., 2005; Kumar-Sinha et al., 2008) being by far the single most common genetic fusion gene in solid tumors (PCAWG Transcriptome Core Group et al., 2020). This evidence concerns the gene TMPRSS2 and prostate cancer.